Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ÆÄ¸Ó½´Æ¼Äà > ½Å°æÁúȯ > ´Ù¹ß¼º°æÈ­Áõ Ä¡·á ½ÃÀå : °æ±¸¾àÀÇ ±âȸ
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4931)
°¨¿°Áúȯ (349)
°ñÁúȯ Ä¡·á (38)
´ç´¢º´ (194)
¹é½Å (181)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (44)
ºñó¹æ ÀǾàǰ (152)
¼öÀÇÇÐ (17)
½Å°æÁúȯ (174)
½Å¾à°³¹ß (1529)
¾ÏÄ¡·á (941)
¾à¹°Àü´Þ (185)
ÀǾàǰ ±ÔÁ¦È¯°æ (127)
Á¤½ÅÁúȯ (86)
Á¦³×¸¯ ÀǾàǰ (128)
Á¦¾àȸ»çºÐ¼® (523)
󹿾à (165)
½ÃÀ庸°í¼­

´Ù¹ß¼º°æÈ­Áõ Ä¡·á ½ÃÀå : °æ±¸¾àÀÇ ±âȸ

Multiple Sclerosis Treatment Market: Opportunities for Oral Drugs

¸®¼­Ä¡»ç Koncept Analytics
¹ßÇàÀÏ 2009³â 03¿ù »óǰÄÚµå 85065
ÆäÀÌÁö Á¤º¸ 29 pages
°¡°Ý
US $ 800 £Ü 953,200 PDF by E-mail (Single User License)
US $ 1,600 £Ü 1,906,400 PDF by E-mail (Corporate Use License)


Koncept Analytics ¿¡¼­ 2009³â 03¿ù ¿¡ ¹ßÇàÇÑ ¡¸´Ù¹ß¼º°æÈ­Áõ Ä¡·á ½ÃÀå : °æ±¸¾àÀÇ ±âȸ¡¹ º¸°í¼­´Â 29 pages·Î ±¸¼ºµÇ¾î, US $800 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.

Çѱ۸ñÂ÷

ÇöÀç ´Ù¹ß¼º°æÈ­Áõ ȯÀÚÀÇ ¾à 36%¸¸ÀÌ Åõ¾àÄ¡·á¸¦ ¹Þ°í ÀÖÀ¸¸ç, ½Å±Ô °æ±¸¾àÀÌ Ãâ½ÃµÊ¿¡ µû¶ó ÀÌ ¼öÄ¡´Â 2014³â±îÁö 56%·Î È®´ëµÉ °ÍÀ¸·Î Àü¸ÁµÇ¾î º» ½ÃÀåÀÇ °æ±¸¾à¿¡ ¹àÀº ±â´ë°¡ ¸ð¾ÆÁö°í ÀÖ½À´Ï´Ù.

¼¼°è ´Ù¹ß¼º°æÈ­Áõ ½ÃÀåÀÇ ¼ö¿ä¿Í ÀáÀçÀû ±âȸ¿¡ ´ëÇØ ºÐ¼®ÇßÀ¸¸ç, ȯÀÚÀÇ ÀÌȯÀ² ¹× Ä¡·á¹ý°ú ÇÔ²² ¾÷°è Âü°¡±â¾÷ÀÇ °³¿ä¿Í ºñÁî´Ï½º Àü·« µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

    Á¦1Àå ¼­·Ð : ´Ù¹ß¼º°æÈ­Áõ
    • ´Ù¹ß¼º°æÈ­Áõ Ä¡·á¸¦ À§ÇÑ FDA Àΰ¡ ¾àÁ¦
    Á¦2Àå ¼¼°èÀÇ ´Ù¹ß¼º°æÈ­Áõ ½ÃÀå
    • ½ÃÀå ±Ô¸ð
    • ÈíÀÔÁ¦ : ½ÃÀå Á¡À¯À²
    Á¦3Àå ¹Ì±¹ÀÇ ´Ù¹ß¼º°æÈ­Áõ ½ÃÀå
    Á¦4Àå ¾÷°è µ¿Çâ
    • ´Ù¹ß¼º°æÈ­Áõ ȯÀÚÀÇ CRPS ÀÌȯÀ²
    • ȯ°æÀÌ ´Ù¹ß¼º°æÈ­Áõ Áõ°¡ÀÇ ¿äÀÎ
    • ³²¼ºÈ¯ÀÚ¿¡ ºñÇØ ¿©¼ºÈ¯ÀÚÀÇ ºñÀ²ÀÌ Áõ°¡
    • ´Ù¹ß¼º°æÈ­Áõ Áø´Ü¼ÒÀÇ ¼ö¿ä
    Á¦5Àå ±âȸ
    • ÈíÀÔ½Ä ¾àÁ¦·ÎÀÇ ±³Ã¼
    • ¾Æ½Ã¾Æ Áö¿ªÀÇ ±âȸ
    Á¦6Àå °æÇÕ È¯°æ
    Á¦7Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Teva Pharmaceutical Industries
    • Biogen
    • Elan Corporation
    • Merck Serono S.A.
    Á¦8Àå ½ÃÀå Àü¸Á
ksa
Back to Top